Integrated pharma maker of branded formulations, generic exports & synthetic APIs; immunosuppressant segment leader.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 |
| Reserves | 163 | 203 | 243 | 294 | 362 | 517 | 541 | 592 |
| Borrowings | 12 | 2 | 1 | 0 | 0 | 0 | 0 | 20 |
| Other Liabilities | 78 | 85 | 88 | 112 | 138 | 127 | 152 | 168 |
| Total Liabilities | 267 | 303 | 345 | 419 | 513 | 658 | 706 | 793 |
| AssetsFixed Assets | 123 | 113 | 104 | 124 | 114 | 172 | 179 | 197 |
| CWIP | 10 | 12 | 31 | 25 | 96 | 16 | 27 | 23 |
| Investments | 0 | 0 | 0 | 58 | 91 | 127 | 93 | 120 |
| Other Assets | 134 | 178 | 210 | 211 | 212 | 343 | 407 | 454 |
| Total Assets | 267 | 303 | 345 | 419 | 513 | 658 | 706 | 793 |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 46 | 50 | 58 | 65 | 91 | 94 | 78 | 56 |
| Cash from Investing | -19 | -11 | -8 | -35 | -106 | -79 | -42 | 51 |
| Cash from Financing | -26 | -39 | -10 | -14 | -17 | -20 | -27 | -21 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 26 | 39 | 50 | 41 | 58 | 25 | 151 | -9 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (37.1×) and current (50.0×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 10.3% growth and a 37× exit, ₹2860 only delivers your return if you pay ₹1,488. The price is currently baking in 24% growth.
EPS grows 10.3%/yr for 5 years, then fades to 6% over 2, exits at 37×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 10.3% | 63.05 |
| FY28 | 10.3% | 69.54 |
| FY29 | 10.3% | 76.70 |
| FY30 | 10.3% | 84.60 |
| FY31 | 10.3% | 93.32 |
| FY32 | 8.2% ·fade | 100.92 |
| FY33 | 6.0% ·fade | 106.98 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.